A5036258389- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- IL-33, ST2, and ILC Pathways
- T-cell and Retrovirus Studies
- PARP inhibition in cancer therapy
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- interferon and immune responses
- Influenza Virus Research Studies
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- T-cell and B-cell Immunology
- Epigenetics and DNA Methylation
- Immune cells in cancer
- Eosinophilic Esophagitis
- Phagocytosis and Immune Regulation
- Ferroptosis and cancer prognosis
- Cancer Diagnosis and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Colorectal Cancer Treatments and Studies
- Animal Virus Infections Studies
- Head and Neck Cancer Studies
Princess Margaret Cancer Centre
2019-2025
University Health Network
2013-2025
University of Toronto
2011-2024
Health Net
2018-2019
Canada Research Chairs
2012-2017
Toronto General Hospital
2011-2017
Chinese Academy of Sciences
2007
Abstract Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer types. Yet, limited data exist show the relationship between ctDNA dynamics genome microenvironment in patients receiving ICB. Here, we present an in-depth analysis of clinical, whole-exome, transcriptome, profiles 73 with advanced solid tumors, 30 types, from phase II basket clinical trial pembrolizumab...
Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified data on post-immunotherapy progression are lacking. We explored the combination of checkpoint inhibitor (nivolumab) an agent (cabozantinib) immunotherapy-naïve cancer patients whose disease progressed previous with baseline biopsy immune profiling.In this phase II trial (ClinicalTrials.gov NCT03367741, registered December 11,...
Abstract Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most research on T cell exhaustion and PD-1 blockade has been focused conventional αβ cells, contribution innate-like cells such as γδ anti-PD-1/PD-L1 mediated therapy is limited. Here we show that tumor reactive respond Merkel carcinoma (MCC) patient experiencing complete response therapy. We find clonally expanded blood after pembrolizumab treatment, this Vγ2Vδ1...
<h3>Background</h3> B7-H3 and B7-H4 are highly expressed by many human malignancies making them attractive immunotherapeutic targets. However, their expression patterns immune contexts in epithelial ovarian cancer have not been well characterized. <h3>Methods</h3> We used flow cytometry, immunohistochemistry, genomic analyses to determine the of B7-H3, B7-H4, PD-L1 tumor, stromal, cells tumor microenvironment (TME). analyzed cell frequency PD-1, TIM3, LAG3, ICOS, TIA-1, granzyme B, 2B4,...
Abstract Purpose: Proliferation of T-follicular helper (TFH) CD4+ T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible costimulator (ICOS) highly expressed by TFH, representing potential target. MEDI-570 monoclonal antibody against ICOS, which eliminates ICOS+ in preclinical models. Patients and Methods: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD), clinical activity T-NHL. NCI-9930 phase I, first-in-human study...
Background Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase M1 M2-polarized tumor-associated macrophages ratio in tumor microenvironment have synergistic antitumor activity combination with anti-programmed death-1/ligand-1 agents. SNOW window-of-opportunity study designed evaluate immune molecular effects of preoperative sitravatinib nivolumab patients oral cavity squamous cell carcinoma. Methods Patients...
Immunotherapy has shown modest activity in metastatic breast cancer (MBC). In this phase I dose escalation study, we assessed safety of tremelimumab, a humanized anti-CTLA4 monoclonal antibody, at starting 3 mg/kg, on the third day palliative radiotherapy (2000cGy 5 daily fractions) patients with MBC. Primary objective was to determine maximum tolerated (MTD) tremelimumab combined RT. Secondary assess response. Among 6 enrolled between July 2010 and October 2011, had hormone...
602 Background: Combination approaches of immune-checkpoint inhibitors and locoregional therapies have an increasing role in advanced HCC. Methods: The PEMRAD phase II trial investigated the efficacy combination pembrolizumab stereotactic body radiation (SBRT) following progression on sorafenib. Patients with HCC, ECOG 0-1 Childs-Pugh A were eligible. received day 1 followed by SBRT starting Day 2 delivered five fractions. Pembrolizumab was continued every 21 days until progression,...
493 Background: Metastatic gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with an overall poor prognosis. The tumour microenvironment (TME) between the primary and metastatic compartment not well characterized. This study aims to describe immunogenomic features of matched GEA their correlation clinical outcomes. Methods: We performed whole exome sequencing (WES, n=36) total RNA (RNA-seq, on prospectively collected cohort GEA, which 14 had tissues. used TME deconvolution...
Immunotherapies have had unprecedented success in the treatment of multiple cancer types, albeit with variable response rates. Unraveling complex network immune cells within tumor microenvironment (TME) may provide additional insights to enhance antitumor immunity and improve clinical response. Many studies shown that NK or innate lymphoid (ILC) regulatory capacity. Here, we identified CD103 as a marker was found on CD56+ were associated poor proliferative capacity tumor-infiltrating...
<div>Abstract<p>Immunotherapies have had unprecedented success in the treatment of multiple cancer types, albeit with variable response rates. Unraveling complex network immune cells within tumor microenvironment (TME) may provide additional insights to enhance antitumor immunity and improve clinical response. Many studies shown that NK or innate lymphoid (ILC) regulatory capacity. Here, we identified CD103 as a marker was found on CD56<sup>+</sup> were associated...
<p>Fig. S10. CD103+Lin- ILC1-like cells are associated with altered immune landscape within the TME.</p>
<p>Fig. S5. Identifying cellular clusters from scRNA-seq of ovarian tumours.</p>
<p>Fig S4. CD101 and GITR expression is expressed on CD103+CD49a+CD56+Lin- ILCs but not other NK cell subsets.</p>
<p>Fig. S1. Gating strategy for intratumoural ILCs.</p>